Meet the Section Editor

Constantinos   Marios   Mikelis

doi:10.2174/1570159X2201230921145913

« Previous Next »

[1]
Mikelis, C.M.; Simaan, M.; Ando, K.; Fukuhara, S.; Sakurai, A.; Amornphimoltham, P.; Masedunskas, A.; Weigert, R.; Chavakis, T.; Adams, R.H.; Offermanns, S.; Mochizuki, N.; Zheng, Y.; Gutkind, J.S. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. Nat. Commun.,  2015, 10(6), 6725.
 [http://dx.doi.org/10.1038/ncomms7725]

[2]
Lahooti, B.; Akwii, R.G.; Zahra, F.T.; Sajib, M.S.; Lamprou, M.; Alobaida, A.; Lionakis, M.S.; Mattheolabakis, G.; Mikelis, C.M. Targeting endothelial permeability in the EPR effect. J. Control. Release,  2023, 361, 212-235.
 [http://dx.doi.org/10.1016/j.jconrel.2023.07.039]

[3]
Zahra, F.T.; Sajib, M.S.; Ichiyama, Y.; Akwii, R.G.; Tullar, P.E.; Cobos, C.; Minchew, S.A.; Doçi, C.L.; Zheng, Y.; Kubota, Y.; Gutkind, J.S.; Mikelis, C.M. Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological in vivo angiogenesis. Sci. Rep.,  2019, 9(1), 11666.
 [http://dx.doi.org/10.1038/s41598-019-48053-z]

[4]
Ziogas, A.; Sajib, M.S.; Lim, J.H.; Alves, T.C.; Das, A.; Witt, A.; Hagag, E.; Androulaki, N.; Grossklaus, S.; Gerlach, M.; Noll, T.; Grinenko, T.; Mirtschink, P.; Hajishengallis, G.; Chavakis, T.; Mikelis, C.M.; Sprott, D. Glycolysis is integral to histamine-induced endothelial hyperpermeability. FASEB J.,  2021, 35(3), e21425.
 [http://dx.doi.org/10.1096/fj.202001634R]

[5]
Akwii, R.G.; Sajib, M.S.; Zahra, F.T.; Tullar, P.; Zabet-Moghaddam, M.; Zheng, Y.; Gutkind, J.S.; Doci, C.L.; Mikelis, C.M. Angiopoietin-2-induced lymphatic endothelial cell migration 1 drives lymphangiogenesis via 2 the β1 integrin-RhoA-formin axis. Angiogenesis,  2022, 25(3), 373-396.
 [http://dx.doi.org/10.1007/s10456-022-09831-y]

[6]
Lahooti, B.; Akwii, R.G.; Patel, D.; Shahbazi, N.S.; Lamprou, M.; Madadi, M.; Abbruscato, T.J.; Astrinidis, A.; Bickel, U.; Al-Ahmad, A.; German, N.A.; Mattheolabakis, G.; Mikelis, C.M. Endothelial-specific targeting of RhoA signaling via CD31 antibody-conjugated nanoparticles. J. Pharmacol. Exp. Ther.,  2023, 6, JPET-AR-2022-001384.
 [http://dx.doi.org/10.1124/jpet.122.001384]

Rights & Permissions Print Cite

Article Metrics

21

3

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1570159X2201230921145913	Print ISSN 1570-159X
Publisher Name Bentham Science Publisher	Online ISSN 1875-6190

Current Neuropharmacology

Meet the Section Editor

Related Journals

Related Books